Support Debbie Fund and help find a cure for cervical cancer

        

Team at UCL and Role that they are playing in the project

   Minimize



 

Professor H Calvert

“Professor Hilary Calvert, MB, BChir, MSc, MD, FRCP, FMedSci
Hilary Calvert, trained in Medicine, Mathematics and Biochemistry, was recently appointed the Director of Anticancer Drug Discovery and at the UCL Cancer Institute, London.
His work on new drugs for treating cancer started in the Institute for Cancer Research and the Royal Marsden Hospital, London (1977-89) where he established the use of Carboplatin for the treatment of Ovarian Cancer and devised a formula which allowed the dose to be optimised for each individual patient. He also introduced a new family of drugs based on the vitamin, folic acid. The first of these is called Raltirexed and is in clinical use for Colon Cancer, and later work around the world led to the development of Pemetrexed, a drug used for treating Lung Cancer. Pemetrexed is also the only drug licensed for treating the asbestos-induced cancer, Mesothelioma. Between 1989 and 2009 he led a team at Newcastle University where the first of another new class of drugs, PARP Inhibitors, was developed. PARP Inhibitors are particularly useful in treating familial Breast and Ovarian Cancers.
In 2005 he was awarded the Pfizer Research Innovation Award – an award made annually within Europe but encompassing all areas of science – for his work on developing new anticancer drugs. In 2009 he was the recipient of the British Oncological Association / Pfizer Lifetime Achievement Award.”

 

Professor K Chester

 
Professor Kerry Chester works on developing new treatments using engineered antibodies that specifically seek-and-bind to the cancer cells and either deliver toxic payloads or ‘mark’ the cells for execution by the patient’s natural immune system. Antibody treatments are already successfully used for cancers of the breast, bowel and blood. Kerry’s group are now developing new antibodies to target markers on the surface of cervical cancers. The aim is to use the antibodies to selectively target treatment to the cancer cells without causing damage to healthy tissue.

 

Dr T Meyer

Dr Tim Meyer is a Medical Oncologist with a special interest in antibody based therapies. He trained at UCLH Medical School and obtained a PhD in Cancer Biology from the University of London before completing his specialist training in Medical Oncology. He was appointed Senior Lecturer at UCL in 2002 and is now based in the UCL Cancer Institute where he leads a team focussed on clinical research and developing new drugs to treat cancer. Recent work includes the use of antibodies to target radiotherapy to cancer cells he is currently working on a new antibody based therapy which can be applied to cervical cancer. 
 


Dr. Enrique Miranda-Rota


 
 


Dr. Tim Fenton